Stemline Therapeutics, Inc.:
ELZONRIS, targeted therapy directed to IL-3 receptor (CD123, approved for BPDC; SL-801 an oral small molecule reversible inhibitor of XPO1 in Ph 1 trial; and SL-701 an immunotherapeutic that completed Ph 2 trial in pts w/2nd line GBM
750 Lexington Ave
New York, NY 10022
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by